DYNAMICURE
LIVE

Serial Number

98745375

Owner

DynamiCure Biotechnology, LLC

Attorney

Keith Toms, Esq.

Filing Date

Sep 11, 2024

Add to watchlist:

No watchlists yet
View on USPTO

DYNAMICURE Trademark

Serial Number: 98745375

DYNAMICURE is a trademark filed by DynamiCure Biotechnology, LLC on September 11, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

DynamiCure Biotechnology, LLC (5 trademarks)

Cambridge, MA 02142

Entity Type: 16

Trademark Details

Filing Date

September 11, 2024

Registration Date

Not Registered

Published for Opposition

October 28, 2025

Goods & Services

Research and development services in the field of biologics, namely, antibodies and peptides for the field of autoimmune diseases, autoimmune disorders, metabolic diseases, neurodegenerative diseases, and kidney diseases; Research and development in the pharmaceutical and biotechnology fields for the treatment of autoimmune diseases, autoimmune disorders, metabolic diseases, neurodegenerative diseases, and kidney diseases; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials in the field of autoimmune diseases, autoimmune disorders, metabolic diseases, neurodegenerative diseases, and kidney diseases; Consulting services in the fields of biotechnology, pharmaceutical research and development, and pharmacogenetics in the field of autoimmune diseases, autoimmune disorders, metabolic diseases, neurodegenerative diseases, and kidney diseases; Conducting research for others in the field of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics in the field of autoimmune diseases, autoimmune disorders, metabolic diseases, neurodegenerative diseases, and kidney diseases; All of the foregoing excluding services in the field of neuromuscular disorders and orphan diseases

Pharmaceutical preparations and substances for the treatment of autoimmune diseases and disorders, autoimmune deficiency; Pharmaceutical preparation and substances for the treatment of genetic disorders; Pharmaceutical preparations and substances for the treatment of metabolic diseases; Pharmaceutical preparations and substances for the treatment of neurodegenerative diseases; Pharmaceutical preparations and substances for the treatment of kidney diseases; Diagnostic biomarker reagents for medical purposes; Protein arrays for medical diagnosis purposes; Diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; Diagnostic preparations for medical purposes for detecting the presence of tumors, genetic disorder and autoimmune disorders and conditions; All of the foregoing excluding treatments and diagnostics for neuromuscular disorders and orphan diseases

Filing History

NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Dec 23, 2025 NOAM
ASSIGNED TO EXAMINER
Nov 12, 2025 DOCK
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 28, 2025 NPUB
PUBLISHED FOR OPPOSITION
Oct 28, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 22, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 29, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 23, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 22, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 22, 2025 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Jun 27, 2025 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Jun 27, 2025 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 28, 2025 GNRN
NON-FINAL ACTION E-MAILED
Mar 28, 2025 GNRT
NON-FINAL ACTION WRITTEN
Mar 28, 2025 CNRT
ASSIGNED TO EXAMINER
Mar 21, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 20, 2025 NWOS
NEW APPLICATION ENTERED
Sep 11, 2024 NWAP